An observational study in Heart Valve Diseases, Aortic Valve Disease and Mitral Valve Disease, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Not yet recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Aortic Valve Disease with a site in China — 16 open to participants now, 18 under way, none of them phase 3. Aortic Valve Disease · China.
Among the 27 studies in Aortic Valve Disease with a site in China, this one has the largest planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2026, is one of 13 observational ones, reaches primary completion later than 17 of the 17 other live ones, and was the 27th registered.
235 studies on the registry are indexed under Aortic Valve Disease; 71 are open to participants now.
Browse Aortic Valve Disease studies →16 of the 27 studies in Aortic Valve Disease with a site in China are open now. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 35–80
Mitrassist Lifesciences Limited Co., Ltd. · Sites in China
Ages 50+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 60+
Xijing Hospital · Sites in China
Ages 50–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 46 Aortic Valve Disease studies recruiting now, 34 (74%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 15,000 is above the median of 200 across 107 observational studies indexed under Aortic Valve Disease.
Median enrollment 98 across the 14 interventional studies, 1,000 across the 13 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 27 have an industry lead sponsor. The 10 most frequent:
First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 318 studies on the registry; 91 are open to participants now.
First Affiliated Hospital Xi'an Jiaotong University has 1 study filed under Aortic Valve Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Aortic Valve Disease with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04864145Nanjing First Hospital, Nanjing Medical UniversityTranscatheter Self-expandable Valve Implantation for the Treatment of Severe Native Aortic Regurgitation | 2026-12-30 |
| NCT06818084Ruijin HospitalTRanscAtheter TreatMent of PurE Aortic Regurgitation With VitaFlow Liberty System | 2027-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Aortic Valve Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn about the clinical characteristics, natural course, and long-term outcomes of valvular heart disease in children and adults of all ages. The main questions it aims to answer are:
Participants with valvular heart disease will:
The ATTENTION study is a national, multicenter, observational registry cohort study of patients with valvular heart disease (VHD), led by the First Affiliated Hospital of Xi'an Jiaotong University in collaboration with multiple medical centers across China. The study does not assign any intervention and does not alter routine clinical care. It aims to establish a long-term research platform integrating a clinical database, a longitudinal follow-up cohort, and a standardized biospecimen repository, to characterize clinical phenotypes, the natural history, treatment pathways, cardiac remodeling, and long-term outcomes across the full spectrum of VHD.
The cohort includes a retrospective component and a prospective component. The retrospective cohort comprises eligible patients identified from electronic medical records, laboratory and imaging databases, surgical and interventional records, pathology archives, and existing follow-up records between January 1, 2013 and the date of ethics approval of the amended protocol. The prospective cohort continuously enrolls patients after ethics approval of the amended protocol through December 31, 2045. Each participant is followed for at least 5 years in principle, with overall follow-up planned through December 31, 2050, at 6 months, 12 months, and annually thereafter, supplemented by routine outpatient, inpatient, and telephone follow-up.
Eligible participants are patients of any age and either sex with a confirmed clinical diagnosis of VHD involving the aortic, mitral, tricuspid, or pulmonary valve, or multiple valves, of any etiology (degenerative, rheumatic, congenital, infective, or functional/secondary), any severity, and any treatment status (conservative management, surgical repair or replacement, or transcatheter intervention). Patients with prior valve intervention are not excluded; the date, type, and baseline valve function of prior treatment are recorded. Cohort baseline is defined as the first visit during the observation period at which eligibility criteria are met and core clinical information is available. Events occurring before baseline are distinguished from incident events during follow-up.
Data collected include demographics; etiology, location, and severity of valve disease; cardiac structure and function (echocardiography, and cardiac magnetic resonance, computed tomography, or catheterization when available); comorbidities; laboratory tests; treatments and their changes over time; and clinical events. Stratified analyses are performed by valve involved, etiology, severity and clinical stage, and treatment pathway.
The primary outcome is the first occurrence of all-cause death or hospitalization for heart failure within 5 years of cohort baseline. Secondary outcomes include cardiovascular death; progression of valve disease; first valve intervention; valve reintervention; prosthetic valve- or repair-related complications (adjudicated per applicable consensus standards, including VARC-3); other major cardiovascular events (stroke, systemic thromboembolism, severe arrhythmias, cardiac arrest, cardiogenic shock); repeated heart failure hospitalizations and unplanned cardiovascular hospitalizations; and perioperative or periprocedural outcomes at 30 days, during hospitalization, and at 1 year after valve intervention.
A biospecimen repository is nested within the cohort on a voluntary basis. Research blood samples are collected only as an additional volume at the time of clinically indicated blood draws; valve, myocardial, vascular, and other tissues are collected only as leftover material after clinical and pathological needs are met. Biospecimen collection is not a condition for enrollment or continued follow-up. Molecular and multi-omics analyses of stored samples may be performed in future separately approved substudies.
Statistical analyses include descriptive statistics, Kaplan-Meier estimates, and Cox proportional hazards models, with competing-risk methods for non-fatal outcomes, time-dependent variables for treatments occurring during follow-up, mixed-effects or recurrent-event models for longitudinal and repeated data, and multivariable adjustment accounting for multicenter clustering. The overall cohort size is anticipated to be at least 15,000 participants; formal sample size calculation is not applicable because the registry aims to describe clinical phenotypes and long-term outcomes rather than to test a specific treatment effect.
235 studies on the registry are indexed under Aortic Valve Disease; 71 are open to participants now.
This study's planned enrollment of 15,000 is above the median of 200 across 107 observational studies indexed under Aortic Valve Disease.
Browse Aortic Valve Disease studies →First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 318 studies on the registry; 91 are open to participants now.
Compared within Aortic Valve Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Valve Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The study population comprises patients of all ages with clinically diagnosed valvular heart disease, including aortic, mitral, tricuspid, pulmonary, and multiple valvular diseases, receiving routine medical care at participating centers in China. Patients may receive conservative management, surgical valve repair or replacement, or transcatheter interventions. The retrospective cohort includes eligible patients identified from existing medical records beginning January 1, 2013. The prospective cohort includes patients enrolled following ethics approval of the amended protocol. Patients with relevant cardiovascular or noncardiovascular comorbidities are eligible. Biospecimen availability is not required for participation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional Considerations:
Patients will not be excluded solely because of advanced age, pediatric status, coexisting congenital heart disease, coronary artery disease, cardiomyopathy, heart failure, chronic kidney disease, or other comorbidities.
The availability of biospecimens is not required for enrollment or continued participation. Patients who decline biospecimen collection, have no available specimens, or miss an individual follow-up assessment will not automatically be excluded from the clinical registry. Collection and use of biospecimens are subject to separate applicable consent and ethics approval requirements.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with clinically diagnosed valvular heart disease identified from existing medical records between January 1, 2013, and the date of ethics approval of the amended protocol. Historical clinical characteristics, treatments, and available follow-up outcomes will be collected retrospectively.
Patients with clinically diagnosed valvular heart disease enrolled after ethics approval of the amended protocol. Clinical information and long-term outcomes will be collected prospectively through routine medical care and follow-up, with recruitment continuing through December 31, 2045.
Time to First All-Cause Death or Unplanned Hospitalization for Heart Failure
Time from cohort baseline to the first occurrence of all-cause death or unplanned hospitalization for heart failure, whichever occurs first. Heart failure hospitalization is defined as an unplanned admission for new or worsening heart failure, confirmed by clinical assessment and requiring heart failure-directed treatment. Elective admissions and routine postoperative observation without worsening heart failure are excluded. The outcome will be reported as the time to the first composite event, measured in days, with the cumulative event probability assessed through 5 years.
Time frame: From baseline through 5 years
Cardiovascular Mortality
Time from cohort baseline to death attributed to a cardiovascular cause, including heart failure, myocardial infarction, fatal arrhythmia, stroke, or valvular heart disease-related complications. The date and cause of death will be determined from available medical records, death documentation, and follow-up information. The outcome will be reported as time to cardiovascular death in days and cumulative incidence through 5 years.
Time frame: From baseline through 5 years
Percentage of Participants With Progression of Valvular Heart Disease
Percentage of participants with documented progression of valvular heart disease during follow-up. Progression is defined as worsening of the severity grade of stenosis or regurgitation in at least one affected valve, based on serial echocardiography and applicable guideline-based criteria. Each participant will be counted once upon the first documented progression. The denominator will include participants with sufficient baseline and follow-up assessments to evaluate progression.
Time frame: From baseline through 5 years
Percentage of Participants Undergoing First Valvular Intervention
Percentage of eligible participants undergoing a first therapeutic intervention on a valve without previous intervention at baseline. Interventions include surgical valve repair or replacement, transcatheter valve repair or replacement, or another therapeutic valvular procedure. Eligibility will be determined separately for each affected valve. The first qualifying intervention date will be recorded, and each participant will be counted once for this outcome.
Time frame: From baseline through 5 years
Percentage of Participants Undergoing Repeat Valvular Intervention
Percentage of participants undergoing repeat surgical or transcatheter intervention on a previously treated valve because of valve dysfunction, recurrent disease, infection, or another established clinical indication. The denominator will include participants with a previously treated valve who are observed during follow-up. The first qualifying repeat intervention will be counted once per participant.
Time frame: From baseline through 5 years
Percentage of Participants With Prosthetic Valve or Valve Repair-Related Complications
Percentage of participants with at least one clinically documented prosthetic valve or valve repair-related complication during follow-up. The composite event includes valve thrombosis, structural valve dysfunction, nonstructural valve dysfunction, paravalvular leak, or prosthetic valve infective endocarditis. Each participant will be counted once if any qualifying complication occurs. The denominator will include participants with a prosthetic valve or previous valve repair.
Time frame: From baseline through 5 years
Percentage of Participants With Stroke
Percentage of participants experiencing at least one clinically diagnosed stroke during follow-up. Stroke will be identified from medical records and neurological assessments, supported by brain imaging when available. The date of the first qualifying stroke will be recorded. Each participant will be counted once regardless of the number of subsequent strokes.
Time frame: From baseline through 5 years
Percentage of Participants With Systemic Thromboembolism
Percentage of participants experiencing at least one clinically documented systemic arterial thromboembolic event, excluding stroke, during follow-up. Events will be confirmed using clinical records, imaging examinations, or relevant procedural documentation. Each participant will be counted once upon the first qualifying event.
Time frame: From baseline through 5 years
Percentage of Participants With Clinically Significant Cardiac Arrhythmias
Percentage of participants with at least one clinically significant atrial or ventricular arrhythmia documented during follow-up. Events must be supported by electrocardiography, ambulatory monitoring, implantable cardiac device recordings, or hospital documentation and require clinical assessment or treatment. The measure will be reported as the percentage of participants with any qualifying arrhythmia, with each participant counted once.
Time frame: From baseline through 5 years
Percentage of Participants Experiencing Cardiac Arrest
Percentage of participants experiencing at least one documented cardiac arrest during follow-up, identified through emergency care, hospitalization, resuscitation, or other clinical records. Both fatal and nonfatal cardiac arrest events will be included. Each participant will be counted once upon the first documented event.
Time frame: From baseline through 5 years
Percentage of Participants Developing Cardiogenic Shock
Percentage of participants with at least one episode of clinically diagnosed cardiogenic shock during follow-up. Events will be identified from hospital records documenting circulatory failure attributed to cardiac dysfunction and associated clinical management. Each participant will be counted once upon the first qualifying episode.
Time frame: From baseline through 5 years
Number of Heart Failure Hospitalizations per Participant
Total number of unplanned hospital admissions for new or worsening heart failure per participant during follow-up, including recurrent admissions after the first event. Each qualifying hospitalization will be counted as one event. Admission dates and reasons will be verified from available clinical records. The outcome will be reported as the number of heart failure hospitalizations per participant.
Time frame: From baseline through 5 years
Number of Unplanned Cardiovascular Hospitalizations per Participant
Total number of unplanned hospital admissions for cardiovascular causes per participant during follow-up, including admissions for worsening heart failure, acute coronary syndromes, arrhythmias, stroke, or other clinically established cardiovascular conditions. Each qualifying hospitalization will be counted once. The outcome will be reported as the number of unplanned cardiovascular hospitalizations per participant.
Time frame: From baseline through 5 years
All-Cause Mortality Within 30 Days After Valvular Intervention
Percentage of participants who die from any cause within 30 days after a surgical or transcatheter valvular intervention. The denominator will include participants undergoing a qualifying intervention. Death will be verified using medical records, death documentation, and available follow-up information. The date of the intervention will serve as the time origin.
Time frame: From valvular intervention through postoperative day 30
Stroke Within 30 Days After Valvular Intervention
Percentage of participants experiencing a clinically diagnosed stroke within 30 days after surgical or transcatheter valvular intervention. Stroke will be assessed using documented neurological findings and brain imaging when available. Each participant will be counted once if a qualifying stroke occurs within the specified period.
Time frame: From valvular intervention through postoperative day 30
Major Bleeding Within 30 Days After Valvular Intervention
Percentage of participants experiencing clinically documented major bleeding within 30 days after surgical or transcatheter valvular intervention. Events will be identified from medical records and adjudicated using the applicable prespecified bleeding criteria for the procedure. Each participant will be counted once if at least one qualifying major bleeding event occurs.
Time frame: From valvular intervention through postoperative day 30
Acute Kidney Injury Within 7 Days After Valvular Intervention
Percentage of participants developing acute kidney injury within 7 days following surgical or transcatheter valvular intervention, identified using available serum creatinine measurements and clinical documentation according to applicable Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Each participant will be counted once if acute kidney injury is documented during the specified period.
Time frame: From valvular intervention through postoperative day 7
Permanent Pacemaker Implantation Within 30 Days After Valvular Intervention
Percentage of participants undergoing new permanent pacemaker implantation within 30 days after surgical or transcatheter valvular intervention. Participants with a permanent pacemaker already implanted before the index procedure will be excluded from the denominator. Pacemaker implantation will be confirmed from procedural and medical records.
Time frame: From valvular intervention through postoperative day 30
Repeat Cardiac Surgery Within 30 Days After Valvular Intervention
Percentage of participants requiring unplanned repeat cardiac surgery within 30 days after surgical or transcatheter valvular intervention. Reoperations will be identified from surgical and hospitalization records. Each participant will be counted once if at least one qualifying unplanned reoperation occurs during the specified period.
Time frame: From valvular intervention through postoperative day 30
All-Cause Mortality Within 1 Year After Valvular Intervention
Percentage of participants who die from any cause within 1 year after surgical or transcatheter valvular intervention. The denominator will include participants undergoing a qualifying intervention. Deaths will be identified from medical records, available death documentation, and follow-up information. The intervention date will serve as the time origin.
Time frame: From valvular intervention through 1 year
Change From Baseline in Left Ventricular Ejection Fraction
Change in left ventricular ejection fraction (LVEF), measured by clinically performed transthoracic echocardiography. LVEF is expressed as a percentage. Change from baseline will be calculated as the follow-up LVEF minus baseline LVEF and reported in percentage points. Measurements will be obtained from available routine clinical echocardiographic examinations without study-mandated imaging.
Time frame: Baseline, 6 months, 12 months, and annually through 5 years, as available
Percentage of Participants With Biospecimens Linked to Clinical and Follow-up Data
Percentage of enrolled participants with at least one retained biospecimen linked to baseline clinical information and available follow-up data. Eligible biospecimens include blood, approved body fluids, and residual valvular, myocardial, vascular, or other relevant tissues obtained during routine clinical care with appropriate authorization. Each participant will be counted once regardless of the number or types of specimens available. The denominator will be the total number of enrolled participants. Biospecimen collection is optional.
Time frame: From baseline through 5 years
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2050, 288 months later.
Of 47 non-industry observational studies under Aortic Valve Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 147. This study's planned 288 months is above that.
Counting every sponsor, half of 56 studies reached it within 49 months; a quarter within 23 and three quarters within 97.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital Xi'an Jiaotong University →